Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Alphamab Out-Licenses HER-2 Bispecific to CSPC in $150 Million Agreement

publication date: Aug 24, 2021

Suzhou Alphamab Oncology out-licensed China rights for its anti-HER2 bispecific antibody to CSPC Pharma in a deal worth up to $150 million, plus royalties. JMT-Bio, a CSPC subsidiary, will own KN026 rights for breast cancer and gastric or gastroesophageal junction cancers. It will be responsible for the cost of all clinical trials in China. Alphamab developed KN026 to bind two non-overlapping epitopes of HER2 simultaneously, leading to a dual HER2 signal blockade. More details....

Stock Symbols: (HK: 9966) (HK: 1093)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.